Research

Ropivacaine Analgesia via an Intra-articular Infusion after Total Knee Arthroplasty A Prospective, Randomized, Blinded, Placebo-Controlled Trial

IRB Number: 10049

Institutional Review Board, Hospital for Special Surgery

August 03, 2010

The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.

Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.

For further information, see Understanding Clinical Trials.

Principal Investigator

Charles N. Cornell, M.D.

Co-Investigators

Keith R. Reinhardt M.D.
Denis Nam M.D.
Spencer S. Liu M.D.

Summary

112 patients with at least 12 month follow-up.  Enrollment period 2 years.

Inclusion/Exclusion Criteria

All patients 18- 80 years old with mono-articular knee osteoarthritis indicated for tricompartment primary total knee replacement.

Contact Information

Charles N. Cornell, M.D.
cornellc@hss.edu
212.606.1414



Request an Appointment